Even the lowest dose outperformed existing alternatives
GLP-1 agonist medications are backed by research for their ability to help curb appetite, regulate blood sugar levels, and support healthy weight loss
By using a platform-based solution with multiple options with regards to product performance, pharmaceutical partners can accommodate variability in pipeline products, reduce development and registration complexity, and accelerate time-to-market for high-value, home-administered injectable drugs
In the gastrointestinal tract, GLP-1 binding to its receptors delays gastric emptying, reduce appetite, and increase satiety [11]
28% point to a lack of supply of the drugs, an issue that has been widely reported
Mechanism map How Compounded Tirzepatide is positioned Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist that has shown up to 22.5% body weight reduction in the SURMOUNT trials